Delving into the Latest Updates on TMD-322 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

aromatase

Mechanism

aromatase inhibitors(Aromatase inhibitors)

Therapeutic Areas

NeoplasmsSkin and Musculoskeletal Diseases

Active Indication-

Inactive Indication

Breast Cancer

Originator Organization

Osaka City University

Active Organization-

Inactive Organization

Osaka City University

Drug Highest PhasePendingClinical

First Approval Date-

Regulation-

Author: Takashima, Tsutomu ; Watanabe, Yasuyoshi ; Yano, Tsuneo ; Inano, Akihiro ; Fujii, Hisako ; Yoshida, Suguru ; Hojo, Taisuke ; Tokai, Hidekichi ; Tanaka, Masaaki ; Takahashi, Kazuhiro ; Yamashita, Shinji ; Kusuhara, Hiroyuki ; Takashima, Tadayuki ; Ishii, Akira ; Tazawa, Shusaku ; Hosoya, Takamitsu ; Sugiyama, Yuichi ; Takahashi, Kayo ; Kataoka, Makoto

The aim of the present study is to investigate the pharmacokinetics of our newly developed aromatase inhibitors (cetrozole and TMD-322) in healthy subjects by a cassette microdose strategy. A cocktail of cetrozole and TMD-322 was administered intravenously or orally (1.98 μg for each drug) to six healthy volunteers in a crossover fashion. Anastrozole (1.98 μg) was also included in the oral cocktail. Total body clearance and bioavailability were 12.1 ± 7.1 mL/min/kg and 34.9 ± 32.3% for cetrozole, and 16.8 ± 3.5 mL/min/kg and 18.4 ± 12.2% for TMD-322, respectively. The area under the plasma concentration-time curves of cetrozole and TMD-322 after oral administration was markedly lower than that of anastrozole because of their high hepatic clearance. Two subjects out of six exhibited 4- and 17-fold larger exposure of cetrozole than the others following intravenous and oral administration, respectively. Such variation was not observed for TMD-322 and anastrozole. Extensive metabolism of cetrozole and TMD-322 was observed in the CYP2C19 expression system among the test CYP isoforms (CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4). We report the first clinical investigation of our aromatase inhibitors by a cassette microdose strategy in healthy Japanese subjects. This strategy offers an optional approach for candidate selection as a phase zero study in drug development.

100 Deals associated with TMD-322

Login to view more data